首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   205284篇
  免费   20284篇
  国内免费   12886篇
耳鼻咽喉   1851篇
儿科学   2396篇
妇产科学   2539篇
基础医学   22828篇
口腔科学   3637篇
临床医学   24634篇
内科学   27898篇
皮肤病学   2436篇
神经病学   10434篇
特种医学   7854篇
外国民族医学   106篇
外科学   22792篇
综合类   36786篇
一般理论   22篇
预防医学   14237篇
眼科学   5165篇
药学   22680篇
  206篇
中国医学   13444篇
肿瘤学   16509篇
  2024年   179篇
  2023年   3001篇
  2022年   5151篇
  2021年   8788篇
  2020年   8649篇
  2019年   9614篇
  2018年   6066篇
  2017年   6791篇
  2016年   5423篇
  2015年   9401篇
  2014年   12063篇
  2013年   11372篇
  2012年   16669篇
  2011年   18087篇
  2010年   12311篇
  2009年   9690篇
  2008年   12349篇
  2007年   11606篇
  2006年   11068篇
  2005年   10545篇
  2004年   6919篇
  2003年   6213篇
  2002年   5070篇
  2001年   4212篇
  2000年   4320篇
  1999年   4177篇
  1998年   2368篇
  1997年   2464篇
  1996年   1880篇
  1995年   1846篇
  1994年   1614篇
  1993年   955篇
  1992年   1310篇
  1991年   1145篇
  1990年   912篇
  1989年   860篇
  1988年   776篇
  1987年   614篇
  1986年   461篇
  1985年   398篇
  1984年   189篇
  1983年   157篇
  1982年   91篇
  1981年   121篇
  1980年   77篇
  1979年   109篇
  1978年   52篇
  1977年   50篇
  1976年   42篇
  1974年   44篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.  相似文献   
10.
We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177).  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号